Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q3 2023 · 10-Q
Revenue$40.13M$40.13M+155.1% vs Q3 2022 Net Income-$63.62M-$63.62MN/M vs Q3 2022 EPS Diluted-$0.65-$0.65N/M vs Q3 2022 Operating Income-$63,482,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$85,222,000N/M Margins · derivedOperating margin-158.2%+437.0 pt vs Q3 2022
Net margin-158.5%+424.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 6, 2023 · 37 d after period end